• Greg Hapgood, Maya Latimer, LeeSze TingST0000-0001-8641-456XOlivia Newton John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.University of Melbourne, Melbourne, Victoria, Australia., Bryone Kuss, Stephen Lade, Joshua W D Tobin, Duncan Purtill, Belinda A Campbell, H Miles Prince, Eliza A Hawkes, Jake Shortt, and Dejan Radeski.
• Princess Alexandra Hospital, Brisbane, Queensland, Australia.
• Intern Med J. 2022 Oct 1; 52 (10): 180618171806-1817.

AbstractPeripheral T-cell lymphomas (PTCL) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared with aggressive B-cell lymphomas. However, such outcomes are heavily dependent on subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine and prednisone remain the standard first-line treatment for most aggressive PTCL, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to understand better the pathogenesis of PTCL to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice.© 2021 Royal Australasian College of Physicians.

23 keywords...

hide…